EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis
Galderma's latest press release highlights new data presented at EADV 2026 showing sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis. Additionally, Galderma has begun trading in the Swiss Market Index, joining Switzerland's leading blue chip companies.
